Literature DB >> 8595266

The anti-oligosaccharide antibodies present in sera from patients with motor neuron disease and neuropathy recognize the N-glycolylneuraminic acid containing gangliotetrahexosyl oligosaccharide.

M Carpo1, E Nobile-Orazio, V Chigorno, S Sonnino.   

Abstract

We found that serum antibodies present in the serum of patients with motor neuron disease and neuropathy, which were previously shown to react with the oligosaccharide chain of ganglioside GM1(Neu5Ac), can be recognized and titred using the N-glycolylneuraminic acid containing monosialo-gangliotetrahexosylceramide, GM1(Neu5Gc), which is not a component of normal human cells. The antibody-antigen reaction was abolished by immunoabsorption with the free oligosaccharide chain. This result, together with the knowledge that these antibodies recognize several glycoconjugates, supports the conviction that these antibodies are non-specific for a gangliosidic structure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8595266     DOI: 10.1007/bf00731271

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  26 in total

1.  A new procedure for the extraction, purification and fractionation of brain gangliosides.

Authors:  G Tettamanti; F Bonali; S Marchesini; V Zambotti
Journal:  Biochim Biophys Acta       Date:  1973-01-19

2.  Ganglioside designation.

Authors:  L Svennerholm
Journal:  Adv Exp Med Biol       Date:  1980       Impact factor: 2.622

3.  Guillain-Barré syndrome associated with high titers of anti-GM1 antibodies.

Authors:  E Nobile-Orazio; M Carpo; N Meucci; M P Grassi; E Capitani; M Sciacco; A Mangoni; G Scarlato
Journal:  J Neurol Sci       Date:  1992-06       Impact factor: 3.181

4.  Isolated bovine spinal motoneurons have specific ganglioside antigens recognized by sera from patients with motor neuron disease and motor neuropathy.

Authors:  H Yoshino; N Miyatani; M Saito; T Ariga; A Lugaresi; N Latov; Y Kushi; T Kasama; R K Yu
Journal:  J Neurochem       Date:  1992-11       Impact factor: 5.372

5.  Serum antibodies to GM1, GD1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barré syndrome and controls: correlation and prognosis.

Authors:  F J Vriesendorp; B Mishu; M J Blaser; C L Koski
Journal:  Ann Neurol       Date:  1993-08       Impact factor: 10.422

6.  Lower motor neuron disease in a patient with autoantibodies against Gal(beta 1-3)GalNAc in gangliosides GM1 and GD1b: improvement following immunotherapy.

Authors:  M E Shy; T Heiman-Patterson; G J Parry; A Tahmoush; V A Evans; P K Schick
Journal:  Neurology       Date:  1990-05       Impact factor: 9.910

7.  Gas--liquid chromatographic assay of lipid-bound sialic acids: measurement of gangliosides in brain of several species.

Authors:  R K Yu; R W Ledeen
Journal:  J Lipid Res       Date:  1970-11       Impact factor: 5.922

8.  Geometrical and conformational properties of ganglioside GalNAc-GD1a, IV4GalNAcIV3Neu5AcII3Neu5AcGgOse4Cer.

Authors:  D Acquotti; L Cantù; E Ragg; S Sonnino
Journal:  Eur J Biochem       Date:  1994-10-01

9.  Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies.

Authors:  A Pestronk; V Chaudhry; E L Feldman; J W Griffin; D R Cornblath; E H Denys; M Glasberg; R W Kuncl; R K Olney; W C Yee
Journal:  Ann Neurol       Date:  1990-03       Impact factor: 10.422

10.  Motor neuron syndrome and monoclonal IgM with antibody activity against gangliosides GM1 and GD1b.

Authors:  E Nardelli; A J Steck; T Barkas; M Schluep; F Jerusalem
Journal:  Ann Neurol       Date:  1988-05       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.